CFTC seeks public input on AI compute futures contracts as CME eyes October launch
Reported by Cointelegraph · AI-assisted summary by ChikoCorp AI News Desk
AI-generated summary based on the linked source; not independently verified. This is not investment advice. Verify market-moving details at the original publisher before acting. See our editorial policy, AI content policy, and financial disclaimer.
Summary
The US Commodity Futures Trading Commission (CFTC) is preparing to request public input on futures contracts based on computing capacity, a resource crucial for artificial intelligence. This move follows regulatory submission for review by the White House Office of Management and Budget and may impact the launch timeline of such contracts planned by CME Group and Intercontinental Exchange. CME Group announced it intends to launch two compute futures contracts on October 5, subject to regulatory approval.
Why it matters
The development marks an attempt to establish computing capacity for AI development as a tradable commodity, similar to oil and electricity. This reflects the increasing importance of AI infrastructure, including data centers and computing resources, in the economy and investment markets.
Key context
CME Group and Intercontinental Exchange are working on creating futures products tied to the cost of computing power needed for AI. The CFTC review involves a public comment period expected after the White House completes its evaluation. Market intelligence firm Silicon Data will provide benchmarks for pricing the CME contracts. AI infrastructure spending is estimated by several firms, including TD Lombard and Goldman Sachs, to be about 2% to 2.5% of US GDP this year.
Key numbers and entities
US Commodity Futures Trading Commission (CFTC), CME Group, Intercontinental Exchange, White House Office of Management and Budget, Silicon Data, TD Lombard, Goldman Sachs, Bridgewater Associates. Planned launch date for CME compute futures: October 5. AI infrastructure spending estimate: approximately 2% to 2.5% of US GDP in 2024.
What remains unclear
The exact duration of the public comment period, the specific regulatory questions being considered, and the final timeline for product approval remain uncertain as noted by the ongoing White House review and delay in formal regulatory approval.